Singapore, Aug. 25 -- Taiwan-based Lotus Pharmaceutical Co. has announced a strategic licensing and commercialisation agreement with Alvotech, covering two of Alvotech's candidates in the United States (US) and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi(R) (durvalumab), and AVT87, a proposed biosimilar to Hemlibra(R) (emicizumab).

Imfinzi(R) is an oncology biologic used in the treatment of multiple cancers, which generated global sales of approximately $6.1 billion in 2025. Hemlibra(R) is a biologic for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A that generated global sales of approximately CHF4.8 billion in 2025, equivalent to approximately $5.8 billion....